Merck
CN
所有图片(1)

文件

Y0000774

兰索拉唑

European Pharmacopoeia (EP) Reference Standard

登录查看公司和协议定价
所有图片(1)
别名:
兰索拉唑
经验公式（希尔记法）:
C16H14F3N3O2S
CAS号:
103577-45-3
分子量:
369.36
MDL编号:
MFCD00866873
PubChem化学物质编号:
329831144
NACRES:
NA.24

等级

pharmaceutical primary standard

API family

lansoprazole

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

格式

neat

SMILES string

Cc1c(CS(=O)c2nc3ccccc3[nH]2)nccc1OCC(F)(F)F

InChI

1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)

InChI key

MJIHNNLFOKEZEW-UHFFFAOYSA-N

Gene Information

human ... ATP4A(495) , ATP4B(496)

正在寻找类似产品? Visit 产品对比指南

相关类别

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Lansoprazole for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

相关产品

产品编号
说明
价格

Y0000773

兰索拉唑, European Pharmacopoeia (EP) Reference Standard

1356916

兰索拉唑, United States Pharmacopeia (USP) Reference Standard

1356927

Lansoprazole Related Compound A, United States Pharmacopeia (USP) Reference Standard

PHR1390

兰索拉唑, Pharmaceutical Secondary Standard; Certified Reference Material

1356931

Lansoprazole Related Compound B, United States Pharmacopeia (USP) Reference Standard

BP872

兰索拉唑, British Pharmacopoeia (BP) Reference Standard

BP873

兰索拉唑杂质标准品, British Pharmacopoeia (BP) Reference Standard

PHR3019

Lansoprazole Related Compound A, pharmaceutical secondary standard, certified reference material

PHR2956

Lansoprazole Related Compound B, certified reference material, pharmaceutical secondary standard

象形图

Exclamation mark
GHS07

警示用语：

Warning

危险声明

H315 - H319 - H335

危险分类

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

靶器官

Respiratory system

储存分类代码

11 - Combustible Solids

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

为方便起见，与您过往购买产品相关的文件已保存在文档库中。

访问文档库

难以找到您所需的产品或批次号码？

在网站页面上，产品编号会附带包装尺寸/数量一起显示（例如：T1503-25G）。请确保 在“产品编号”字段中仅输入产品编号 (示例: T1503).

示例

T1503
货号
-
25G
包装规格/数量

其它示例：

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

输入内容 1.000309185)

遇到问题？欢迎随时联系我们技术服务 寻求帮助

批号可以在产品标签上"批“ （Lot或Batch）字后面找到。

Aldrich 产品

  • 如果您查询到的批号为 TO09019TO 等，请输入去除前两位字母的批号：09019TO。

  • 如果您查询到的批号含有填充代码（例如05427ES-021），请输入去除填充代码-021的批号：05427ES。

  • 如果您查询到的批号含有填充代码（例如 STBB0728K9），请输入去除填充代码K9的批号：STBB0728。

未找到您寻找的产品？

部分情况下，可能未在线提供COA。如果搜索不到COA，可在线索取。

索取COA

Yun Jeong Lim et al.
Digestion, 86(2), 171-177 (2012-08-22)
Proton pump inhibitors (PPIs) are widely used to prevent nonsteroidal anti-inflammatory drug (NSAID)-induced peptic ulcers. NSAIDs produce small intestinal injury and some PPIs have been reported to protect against NSAID-induced small bowel injury in rats. The aim of this study
Hiroshi Satoh
Current pharmaceutical design, 19(1), 67-75 (2012-09-07)
The proton pump inhibitors (PPIs) lansoprazole (LPZ) and omeprazole (OPZ) have been widely used for more than 20 years in the treatment of acid-related diseases such as gastro-duodenal ulcers and reflux esophagitis. Both LPZ and OPZ are derivatives of 2-[(2-
Jun-Won Chung et al.
Journal of gastroenterology and hepatology, 27(11), 1675-1680 (2012-08-02)
Increased resistance of Helicobacter pylori to antibiotics has increased the need to develop new first-line treatments for H. pylori. We have prospectively evaluated 10-day sequential versus conventional triple therapy in peptic ulcer patients. One hundred and fifty-nine patients with peptic ulcer
Jyh-Ming Liou et al.
Lancet (London, England), 381(9862), 205-213 (2012-11-20)
Whether sequential treatment can replace triple therapy as the standard treatment for Helicobacter pylori infection is unknown. We compared the efficacy of sequential treatment for 10 days and 14 days with triple therapy for 14 days in first-line treatment. For
Grace Chai et al.
Pediatrics, 130(1), 23-31 (2012-06-20)
To describe trends in outpatient prescription drug utilization in US children and the changes in major areas of pediatric therapeutic use for the years 2002 through 2010. Large prescription databases (the IMS Vector One: National and Total Patient Tracker) were
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门